EFFICACY AND SAFETY OF TRIPLE THERAPY WITH PEGINTERFERON, RIBAVIRIN, AND BOCEPREVIR WITHIN EARLY ACCESS PROGRAM IN SPANISH PATIENTS WITH HEPATITIS C GENOTYPE 1 WITH SEVERE FIBROSIS: SVRW12 ANALISYS

被引：0
|
作者：
Calleja, J. L.
Ruiz, B.
Pascasio, J. M.
Gea, F.
Barcena, R. [1 ]
Larrubia, J. R. [2 ]
Forns, X.
Alvarez, R.
Sola, R.
Romero, M.
Sancho, A.
Salcedo, I.
Fernandez, M. J.
机构：
[1] Univ Hosp Ramon & Cajal, Madrid, Spain
[2] Univ Hosp Guadalajara, Guadalajara, Jalisco, Mexico
来源：
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY | 2013年 / 113卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：32 / 33
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of triple therapy with Peginterferon, Ribavirin, and Boceprevir within Early Access Program in Spanish patients with hepatitis c genotype 1 with severe fibrosis. SVRw12 Analisys
    Luis Calleja, Jose
    Manuel Pascasio, Juan
    Ruiz-Antoran, Belen
    Gea, Francisco
    Barcena, Rafael
    Larrubia, Juan R.
    Manuel Sousa, Jose
    Forns, Xavier
    Perez-Alvarez, R.
    Sola, Ricard
    Romero-Gomez, Manuel
    de la Revilla, Juan
    Arenas, Juan I.
    Delgado, Manuel B.
    Crespo, Javier
    Navarro, J. M.
    Fernandez-Rodriguez, Conrado M.
    Planas, Ramon
    Buti, Maria
    HEPATOLOGY, 2013, 58 : 1116A - 1116A
  • [2] Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis
    Calleja, Jose L.
    Pascasio, Juan M.
    Ruiz-Antoran, Belen
    Gea, Francisco
    Barcena, Rafael
    Larrubia, Juan R.
    Perez-Alvarez, Ramon
    Sousa, Jose M.
    Romero-Gomez, Manuel
    Sola, Ricard
    de la Revilla, Juan
    Crespo, Javier
    Navarro, Jose M.
    Arenas, Juan I.
    Delgado, Manuel
    Fernandez-Rodriguez, Conrado M.
    Planas, Ramon
    Buti, Maria
    Forns, Xavier
    LIVER INTERNATIONAL, 2015, 35 (01) : 90 - 100
  • [3] EFFICACY AND SAFETY OF TRIPLE-THERAPY WITH PEGINTERFERON-RIBAVIRIN, AND BOCEPREVIR AS COMPASSIONATE-USE IN SPANISH PATIENTS WITH HEPATITIS C GENOTYPE 1 WITH SEVERE FIBROSIS: INTERIM-ANALYSIS AT 12 WEEKS
    Calleja, J. L.
    Pascasio, J. M.
    Ruiz-Antoran, B.
    Larrubia, J. R.
    Gea, F.
    de la Revilla, J.
    Forns, X.
    Barcena, R.
    Romero-Gomez, M.
    Crespo, J.
    Sola, R.
    Fernandez, C.
    Fernandez, I.
    Buti, M.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S326 - S327
  • [4] Efficacy, Treatment Duration and Safety of Boceprevir/Peginterferon/Ribavirin in Treatment Naive Patients With Hepatitis C Virus Genotype 1 Infection According to Baseline Fibrosis Score
    Serfaty, Lawrence
    Vierling, John
    Poordad, Fred
    Flamm, Steven L.
    Bacon, Bruce R.
    Deng, Weiping
    Koury, Kenneth J.
    Hagen, Karin
    Alves, Katia
    Wahl, Janice
    HEPATOLOGY, 2013, 58 (06) : 1393A - 1394A
  • [5] COST-EFFECTIVENESS ANALYSIS OF TRIPLE THERAPY WITH PEGINTERFERON, RIBAVIRIN, AND BOCEPREVIR FOR THE TREATMENT OF CHRONIC HEPATITIS C VIRUS GENOTYPE 1 WITH SEVERE FIBROSIS UNDER 'REAL-LIFE' CONDITIONS
    Ruiz-Antoran, B.
    Sancho-Lopez, A.
    Payares, C.
    de la Revilla, J.
    Calleja Panero, J. L.
    Avendano-Sola, C.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2014, 115 : 18 - 18
  • [6] COST-EFFECTIVENESS ANALYSIS OF TRIPLE THERAPY WITH PEGINTERFERON, RIBAVIRIN, AND BOCEPREVIR FOR THE TREATMENT OF CHRONIC HEPATITIS C VIRUS GENOTYPE 1 WITH SEVERE FIBROSIS UNDER "REAL-LIFE" CONDITIONS
    Ruiz-Antoran, B.
    Pascasio, J. M.
    Gea, F.
    Barcena, R.
    Larrubia, J.
    Perez Alvarez, R.
    Sousa, J.
    Romero-Gomez, Manuel
    Sola, R.
    de la Revilla, J.
    Crespo, J.
    Navarro, J.
    Arenas, J.
    Delgado, M.
    Fernandez Rodriguez, C.
    Planas, R.
    Buti, M.
    Forns, X.
    Calleja, J. L.
    VALUE IN HEALTH, 2014, 17 (07) : A367 - A367
  • [7] COST-EFFECTIVENESS ANALYSIS OF TRIPLE THERAPY WITH PEGINTERFERON, RIBAVIRIN, AND BOCEPREVIR FOR THE TREATMENT OF CHRONIC HEPATITIS C VIRUS GENOTYPE 1 WITH SEVERE FIBROSIS UNDER "REAL-LIFE" CONDITIONS
    Ruiz-Antoran, B.
    Pascasio, J. M.
    de la Revilla, J.
    Crespo, J.
    Salcedo de Diego, I.
    Payares, C.
    Forns, X.
    Calleja, J. L.
    Avendano-Sola, C.
    CLINICAL THERAPEUTICS, 2015, 37 (08) : E154 - E154
  • [8] Efficacy and safety of boceprevir based triple therapy in Hungarian patients with hepatitis C genotype 1 infection, advanced stage fibrosis and prior treatment failure
    Hunyady Bela
    Abonyi Margit
    Csefko Klara
    Gervain Judit
    Haragh Attila
    Horvath Gabor
    Jancsik Viktor
    Makkai Erzsebet
    Mueller Zsofia
    Ribiczey Pal
    Sipos Bela
    Szabo Olga
    Szalay Ferenc
    Szentgyorgyi Laszlo
    Tornai Istvan
    Ujhelyi Eszter
    Varga Marta
    Weisz Gyorgy
    Makara Mihaly
    ORVOSI HETILAP, 2016, 157 (34) : 1366 - 1374
  • [9] A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C
    Hara, Tasuku
    Akuta, Norio
    Suzuki, Fumitaka
    Sezaki, Hitomi
    Suzuki, Yoshiyuki
    Hosaka, Tetsuya
    Kobayashi, Masahiro
    Kobayashi, Mariko
    Saitoh, Satoshi
    Kumada, Hiromitsu
    JOURNAL OF MEDICAL VIROLOGY, 2013, 85 (10) : 1746 - 1753
  • [10] Safety and efficacy of boceprevir with peginterferon alfa-2a and weight based ribavirin in liver transplant recipients with genotype 1 hepatitis C virus
    Raines, Alissa
    Dick, Travis B.
    Frech, Edward J.
    Jones, Robert G.
    Boschert, Mark E.
    Harmston, Gordon E.
    HEPATOLOGY, 2013, 58 : 1162A - 1162A
12345